Introduction
Phosphatidyl inositol 3-kinase (PI3K), the major activator of the serine/threonine protein kinase Akt, plays crucial roles in promoting growth, survival, and proliferation of cancer cells [1] . Activation of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway is one of the most frequent molecular events in acute myeloid leukemia (AML), documented in approximately 70 % of patients [2] . PI3K phosphorylates phosphatidyl 4,5-bisphosphate to produce a second messenger, phosphatidylinositol 3,4,5-trisphosphate, which in turn promotes the activation of downstream kinases, including Akt and mTOR [1] . PI3Ks are divided into three classes, I, II, and III, according to their structural characteristics and substrate specificity. Of these, only the class I PI3Ks, comprising the p110α, β, δ, and γ isoforms, are able to generate Linhua Jin and Yoko Tabe contributed equally to this work.
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The online version of this article (doi:10.1007/s00109-013-1076-3) contains supplementary material, which is available to authorized users. phosphatidylinositol 3,4,5-triphosphate through activation of phosphoinositide-dependent kinase 1, which subsequently phosphorylates and activates Akt [1] . Since this pathway is an attractive therapeutic target in cancer, novel PI3K isoformspecific inhibitors have been developed as potential chemotherapeutic drugs and have entered clinical trials [3] . GDC-0941 (Fig. 1a) is a selective oral inhibitor of class I PI3K isoforms (median inhibitory concentrations [IC 50 ]: 3nM for PI3K-α, 33nM for PI3K-β, 3nM for PI3K-δ, and 75nM for PI3K-γ); it has promising pharmaceutical properties [4] and currently is being evaluated in Phase I clinical trials [3, 4] .
The Bcl-2 family proteins are master regulators of apoptotic cell death through the mitochondrial pathway and have been identified as targets for cancer treatment [5] . Interactions between proapoptotic and antiapoptotic Bcl-2 family proteins dictate the fate of a cell following an apoptotic stimulus. The antiapoptotic members of the Bcl-2 family, Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bfl-1, share sequence homology in four alphahelical Bcl-2 homology domains (BH), BH1-BH4 [5] , and are known to be regulated by the Stat5 or PI3K/Akt pathways [6, 7] . The multidomain proapoptotic proteins Bax, Bak, and Bad, the promoters of apoptosis, share homology in domains BH1 through BH3 [5] . Overexpression of antiapoptotic Bcl-2 family proteins is frequent in human cancer, and several novel agents that target these antiapoptotic Bcl-2 family proteins have been developed [8] . ABT-737 (Fig. 1b) is a potent and selective small-molecule antagonist of antiapoptotic Bcl-2 family proteins [9] . ABT-737 binds to the hydrophobic BH3-binding groove of antiapoptotic Bcl-2 family members Bcl-xL, Bcl-2, and Bcl-w with nanomolar affinity and exerts its proapoptotic function by preventing antiapoptotic Bcl-2 family members from sequestering activating BH3 proteins [9] . ABT-737 sensitizes cancer cells to conventional cytotoxic drugs in vitro and in vivo [8] , and we showed its single-agent activity in AML [10] . However, ABT-737 has poor affinity for antiapoptotic Mcl-1, a downstream target in the PI3K/Akt pathway, and increased cellular Mcl-1 levels were found to be associated with resistance to ABT-737 [8, 10, 11] . Since Mcl-1 is critical for survival of human AML cells [12] , targeting of Mcl-1 or regulators of its expression in combination with ABT-737 may be a useful strategy for the treatment of AML.
Hypoxia and interactions with bone marrow (BM) stromal cells are essential components of the leukemic BM microenvironment in promoting AML cell survival and chemoresistance [13] . We recently showed that leukemia progression is associated with vast expansion of hypoxia in bone marrow microenvironment and that hypoxia contributes to chemoresistance of leukemic cells [13, 14] . Hypoxia-inducible factor-1 alpha (HIF-1α), one of the best characterized markers of hypoxia, is a transcription factor that controls gene products involved in energy metabolism, angiogenesis, apoptosis, and cell-cycle regulation and has become recognized as a strong promoter of tumor growth [15] . Hypoxia activates the PI3K/ Akt signaling pathway [16] , which may be one mechanism for leukemic cells to adapt and survive under conditions of hypoxia [17] . Notably, HIF-1α-independent downregulation of Mcl-1 has been reported to sensitize tumor cells to ABT-737-induced cell death under hypoxic conditions in colorectal carcinoma and small cell lung cancer [18] .
In light of the known roles in cell survival of PI3K/Akt/ mTOR signaling and antiapoptotic Bcl-2 family members, the potential modulation of Mcl-1 by PI3K pathway and the possible Mcl-1 downregulation under hypoxic conditions, we hypothesized that GDC-0941 and ABT-737 would effectively suppress AML cell survival in the hypoxic BM microenvironment. In this study, we investigated the antileukemic efficacy of simultaneous blockade of PI3K and antiapoptotic Bcl-2 pathways, which may constitute a targeted approach to eradicate chemoresistant AML cells sequestered in hypoxic BM niches.
Materials and methods
Cell lines and culture conditions Acute myeloid leukemia cell lines were cultured in RPMI 1640 medium containing 10 % heat-inactivated fetal bovine serum (FBS), 1 % L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in 5 % CO 2 . MOLM-13 cells were kindly provided by Hayashibara Biochemical Laboratories (Okayama, Japan). HL-60 and MV4;11 cells were purchased from the American Type Culture Collection (Rockville, MD), and OCI-AML3 cells were from DSMZ (Braunschweig, Germany). Primary AML samples were obtained after informed consent in accordance with institutional guidelines set forth by Aichi Medical University per Declaration of Helsinki principles. Mononuclear cells were purified by Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO) density-gradient centrifugation, and nonadherent cell were resuspended in RPMI 1640 medium supplemented with 10 % FBS at a density of 6×10 6 cells/mL. Clinical characteristics of patients are summarized in Supplementary Table 1 .
Mesenchymal stem cells (MSCs) obtained from healthy BM donors and AML patients were cultured at a density of 5,000 to 6,000 cells/cm 2 in minimum essential medium alpha supplemented with 20 % FBS, 1 % L-glutamine, and 1 % Fig. 1 Chemical structures of GDC-0941 and ABT-737 penicillin-streptomycin as described elsewhere [19] . The isolated, cultured MSCs at passage 3 comprised a single phenotypic population, as determined by flow cytometric analysis, positive for SH2 and SH3 and negative for markers of hematopoietic lineage. Passage 3 or 4 MSCs were used for the coculture experiments. To study the effect of BM stroma on AML cells, MOLM-13 and HL-60 cells were cultured at a density of 5×10 5 , with or without a layer of MSCs plated at a density of 0.2×10 5 cells/cm 2 . Co-cultured AML cells were separated from the MSC monolayer by careful pipetting with ice-cold phosphate-buffered saline solution (PBS), repeated twice. After the AML cells were collected, to rule out the possibility of contamination with MSCs, MSC monolayers were examined by microscopy (×100) to confirm that the monolayer was not damaged and that fewer than ten leukemic cells per visual field remained attached. To verify lack of significant contamination in collected leukemic cells, the expression of CD45 was measured by flow cytometry as a discriminator between leukemic cells and MSCs [19] . Data were acquired and analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA). In indicated experiments, co-cultures were performed in the presence of the class I PI3K isoform inhibitor GDC-0941 (Genentech Inc, South San Francisco, CA) and/or the BH-3 mimetic agent ABT-737 (Abbott Laboratories, IL). Chemical structures are shown in Fig. 1 . The MEK inhibitor U0126 was purchased from Calbiochem (San Diego, CA). For hypoxia experiments, leukemic cells from AML cell lines were cultured in a 1 % O 2 environment for at least 7 days to assure their continuous proliferation and survival.
Isolation of CD34
+ cells Normal bone marrow CD34 + cells were obtained with informed consent from patients undergoing routine diagnostic procedures for nonmyeloid hematopoietic disorders. CD34 + cells were isolated from mononuclear cell preparations, as previously described [20] .
Lentiviral transduction of Mcl-1 shRNA Mcl-1 expression was silenced by infecting OCI-AML3 cells with short hairpin RNA (shRNA)-encoding oligonucleotide targeting Mcl-1 as described elsewhere [10] . The cells infected Mcl-1shRNA or scrambled control shRNA were monitored for GFP fluorescence and treated with GDC-0941 and/or ABT-737.
Cell viability, apoptosis, and cell-cycle analysis Cell viability was assessed by the trypan blue dye exclusion method. Apoptotic cell death was analyzed by annexin V staining. Briefly, fresh cells were washed twice with binding buffer (10 mM HEPES, 140 mM NaCl, and 5 mM CaCl 2 , pH 7.4) and then stained with fluorescein isothiocyanate-conjugated annexin V (Roche Diagnostics, Indianapolis, IN) and propidium iodide (PI). Annexin V fluorescence was quantified by a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems). To measure mitochondrial membrane potential (Δψ m ), cells were loaded with MitoTracker Red CMXRos (300 nM) and MitoTracker Green (100 μM, both from Molecular Probes, Eugene, OR) for 1 h at 37°C. The Δψ m was then assessed by measuring CMXRos retention (red fluorescence) while simultaneously adjusting for mitochondrial mass (green fluorescence). The flow cytometric data were analyzed by CellQuest software.
Cell-cycle distribution was analyzed by flow cytometric analysis of PI-stained nuclei. Cells were fixed in ice-cold ethanol (70 % vol/vol) and stained with PI solution (25 μg/ml PI, 180 U/ml RNase, 0.1 % Triton X-100, and 30 mg/ml polyethylene glycol in 4 mM citrate buffer, pH 7.8; SigmaAldrich, St. Louis, MO). DNA content was determined by a FACScan flow cytometer system, using CellQuest software for data acquisition and analysis. Gating was set to exclude cell debris, cell doublets, and cell clumps. Flow cytometric analysis of BAX activation BAX conformational change was analyzed as previously described [21] . Cellular fixation, permeabilization, and staining with primary antibody or an isotypic control were performed using the Dako IntraStain kit (DakoCytomation, Carpinteria, CA), according to the manufacturer's instructions. Staining with conformationspecific monoclonal antibody against BAX (YTH-6A7; Trevigen, Gaithersburg, MD) and isotype-matched control antibody was performed with a 1:200 dilution in 100 μl of staining buffer. Then, cells were washed three times, resuspended in 100 μl of staining buffer containing 1 mg of Alexafluor 488-labeled chicken anti-rabbit IgG (Molecular Probes), and incubated on ice for 30 min in the dark. After three washes, activation-specific BAX was immediately measured.
Statistical analysis Synergism, additive effects, and antagonism were assessed by the Chou-Talalay method [22] , utilizing Calcusyn software (Biosoft, Cambridge, UK). The effect on cellular proliferation was shown as a percentage reduction of cell viability when compared with dimethyl sulfoxide (DMSO)-treated controls. The average combination index (CI) value for the experimental combination was calculated from the 50, 75, and 90 % effective doses (ED 50 , ED 75 , and ED 90 ). By this method, CI values indicate the following: 0.3-0.7, strong synergism; 0.7-0.85, moderate synergism; 0.85-0.9, slight synergism; 0.9-1.1, nearly additive; 1.1-1.2, slight antagonism; 1.2-1.45, moderate antagonism; 1.45-3.3, antagonism; and 3.3-10, strong antagonism [22] .
Results
Antiproliferative effects of the GDC-0941 and ABT-737 combination in AML cells We first examined the effect of the class I PI3K isoform inhibitors GDC-0941 and the BH-3 mimetic agent ABT-737 on the proliferation of cultured AML cell lines. AML cells were treated with GDC-0941, ABT-737, or their combination for 48 h, and the numbers of viable cells were measured. The GDC-0941 concentrations used were 0, 0.25, 0.5, or 1.0 μM, and the ABT-737 concentrations were 0, 0.025, 0.05, or 0.1 μM; the concentration ratio of GDC-0941 to ABT-737 was kept constant at 10:1. As shown in Fig. 2a , GDC-0941 treatment resulted in dose-dependent cell growth inhibition in AML cells, with OCI-AML3 cells being relatively resistant to the compound (IC 50 : 1.0 μM for MOLM-13, 1.1 μM for HL-60, 0.7 μM for MV4;11, 4.7 μM for OCI-AML3). No significant difference in ABT-737 sensitivity was noted between wild-type p53 MOLM-13, MV4;11 cells (IC 50 0.04 and 0.03 μM) and p53-deleted HL-60 cells (IC 50 0.02 μM), concordant with a previous report [9] . However, OCI-AML3 cells, known to express high levels of Mcl-1 [23] were resistant to ABT-737 (IC 50 15.7 μM). Isobologram analysis demonstrated synergistic nature of pharmacological interactions between GDC-0941 and ABT-737, causing profound cell growth inhibition in HL-60, MOLM-13, and MV4;11 cells (Fig. 2b) . Although combined use of ABT-737 and GDC-0941 caused significant reduction of viable cell numbers in ABT-737-resistant OCI-AML3 cells (CI=0.54), the effects remained modest even at highest concentrations of both agents used (Fig. 2a) .
We next tested the effects of GDC-0941 and ABT-737 in primary AML samples with high blast count (Supplementary Table 1 ). GDC-0941 induced moderate cell growth inhibition in 3/4 primary AML samples (Pt #2, 3, 4), and ABT-737 caused more profound reduction in viability (Fig. 2c) . Combination of GDC-0941 and ABT-737 resulted in further decrease in viable cell numbers with corresponding increase in fraction of trypan blue (+) blast cells in all primary AML samples tested. In turn, no significant cell growth suppression or apoptosis induction was observed in normal bone marrowderived CD34 + cells treated by 0.5 μM GDC-0941, 0.05 μM ABT-737, or both under normal MSCs co-culture conditions ( Supplementary Fig. 1 ).
We previously reported that MEK/ERK pathway inhibition potently synergizes with ABT-737 in inducing apoptosis in AML cells [24] , at least in part through Mcl-1 modulation. Because combined use of GDC-0941 and ABT-737 caused a reduction of cell viability in Mcl-1-overexpressing ABT-737-resistant OCI-AML3 cells, we investigated whether the inhibition of MEK/ERK pathway could further enhance the effects of GDC-0941/ABT-737. The MEK inhibitor U2016, however, showed no further increase in growth-inhibitory or proapoptotic effects of GDC-0941/ABT-737 combination (data not shown), indicating that PI3K/Akt and MAPK pathways confer resistance to ABT-737 through redundant downstream pathways in AML cells with high levels of Mcl-1.
GDC-0941 increases ABT-737-induced apoptosis in AML cells co-cultured with MSC under hypoxic conditions BMderived stromal cells are known to activate pro-survival Akt signaling in co-cultured leukemic cells [19] , and hypoxia is reported to increase activation of the PI3K/Akt/mTOR pathway [25] . In turn, both may contribute to leukemic cell adaptation and survival in the BM microenvironment [17] . The antiapoptotic Bcl-2 family members, such as Mcl-1 and Bcl-X L , are the downstream targets of Akt and mTOR signaling [26] . Hypoxia-induced mTOR activation is modulated in a PI3K/Akt-dependent [27] and -independent manner [28] , while mTOR itself mediates the downstream signaling of PI3K/Akt through TORK2-dependent phosphorylation of Akt [29] . GDC-0941 has high potency against class I PI3Ks, but less against mTOR [4] .
We, therefore, investigated whether MSC-leukemia cell interaction or hypoxia affects GDC-0941-and ABT-737-induced inhibition of AML cell growth. MOLM-13, HL-60, and OCI-AML3 cells co-cultured with normal MSCs under normoxic and hypoxic conditions were exposed to 0.5 μM GDC-0941, 0.05 μM ABT-737, or both for 48 h. As shown in Fig. 3a , in MOLM-13 and HL-60 cells, MSC had no significant protective effect against GDC-0941-or ABT-737-induced cell growth inhibition. Hypoxia on its own decreased the cell growth of MOLM-13 and HL-60 cells, which translated in less potent growth suppression by GDC-0941 or ABT-737. Curiously, hypoxia rendered resistant OCI-AML3 cells sensitive to ABT-737 (Fig. 3a) . The combination of GDC-0941 and ABT-737 significantly inhibited cell proliferation irrespective of oxygen concentration in the tested cells except OCI-AML3 in normoxia. GDC-0941 (0.5 μM) treatment resulted in G 1 -phase cell-cycle arrest without significant apoptosis induction under normoxic and hypoxic conditions in MOLM-13 cells and under normoxic conditions in HL-60 and OCI-AML3 cells (Fig. 3b, c; Supplementary Fig. 1A, B) . Fig. 2 Synergistic interaction between GDC-0941 and ABT-737 in AML cells. a MOLM-13, HL-60, MV4;11, and OCI-AML3 cells were cultured in the presence of escalating doses of GDC-0941 and ABT-737 using fixed ratios. After 48 h, the effects on cell growth were evaluated by viable cell counts using the trypan blue exclusion method. Graphs show the mean±SEM of results of three independent experiments. b Combination index (CI) plots were generated using CalcuSyn software (crosses represent actual data points for the GDC-0941 and ABT-737 combination). The averaged CI values calculated from the values for ED 50 , ED 75 , and ED 90 . The values less than 1.0 indicate synergism. c Primary AML cells (n=4) were incubated for 48 h with 0.5 μM GDC-0941, 0.05 μM ABT-737, or both. Clinical characteristics of patients are summarized in Supplementary Table 1 Consistent with published reports in solid tumors [27] , hypoxia promoted accumulation in quiescent state of MOLM-13 cells and less so of HL-60 cells. On the other hand, ABT-737 caused significant increases in annexin Vpositive fractions in MOLM-13 and HL-60 cells (Fig. 3c,  p<0 .05). The combination of GDC-0941 and ABT-737 resulted in further increases in apoptosis and was equally potent in normoxic and hypoxic conditions with or without MSC co-culture (Fig. 3c, Supplemental Fig. 1B ). These findings suggest that blockade of PI3K combined with ABT-737 in the hypoxic condition exerts apoptotic efficacy against AML cells. Consistent with viability results in OCI-AML3 cells that are resistant to ABT-737 in normoxic condition, hypoxic condition reversed the resistance to ABT-737 in both suspension culture and MSC co-culture. In these Mcl-1 expressing cells, the combination with GDC-0941 further inhibited cell proliferation with increased apoptotic cell death under hypoxic condition.
Since these studies were conducted using normal BMderived MSCs, we next investigated whether MSCs derived from AML patients are more efficient in protecting AML cells against GDC-0941-or ABT-737-induced cell death. While no significant difference was seen in response to PI3K inhibitor, AML patient BM-derived Fig. 3 Combination of GDC-0941 and ABT-737 induces apoptosis in AML cells under normoxic and hypoxic and MSC co-culture conditions. MOLM-13, HL-60, and OCI-AML3 cells were incubated for 48 h with 0.5 μM GDC-0941, 0.05 μM ABT-737, or both, in the presence of absence of MSCs from three normal subjects under normoxic or hypoxic conditions. The viable cell numbers were measured by trypan blue exclusion assay (a). The DNA content (b) and annexin V-positive fractions (c) were measured by flow cytometry. Graphs show the means±-SEM of results of three independent experiments. *p<0.05, **p<0.01
MSCs conferred improved protective effects against GDC-0941/ABT-737 combination in MOLM-13 and HL-60 cells (Supplementary Fig. 3 ).
GDC-0941 and/or ABT-737 induce Mcl-1 downregulation under hypoxic conditions in AML cells
To investigate the molecular events that contribute to apoptosis induced by the combination of GDC-0941 and ABT-737, we treated ABT-737-sensitive MOLM-13 and ABT-resistant OCI-AML3 cells with GDC-0941, ABT-737, or both, with or without MSC coculture, under normoxic or hypoxic conditions; PI3K/Akt/ mTOR signaling factors and pro-and antiapoptotic protein levels were investigated (Fig. 4) . Hypoxia increased phosphorylation of Akt in MOLM-13 cells but not in OCI-AML3 cells. However, in both cells, the Akt phosphorylation was effectively blocked by GDC-0941 both in normoxic and hypoxic conditions. Whereas GDC-0941 inhibited phosphorylation of mTOR downstream target S6K in normoxic condition, hypoxia itself or MSC co-culture under hypoxia interfered with the ability of GDC-0941 to block mTOR signaling recognized by p-S6K downregulation in OCI-AML3 or MOLM-13 cells, respectively. ABT-737 did not significantly affect phosphorylation of Akt or S6K. Neither GDC-0941 nor ABT-737 affected HIF-1α expression.
Given the role of Bcl-2 family members in regulation of apoptosis, we examined the effects of GDC-0941 on the expression levels of Bcl-2 family proteins. It was shown recently that Mcl-1 levels in cancer cells are consistently lower in hypoxic conditions than in normoxic conditions [18] , and our observations were consistent with that both in MOLM-13 and OCI-AML3 cells. Especially in OCI-AML3 cells that were resistant to ABT-737 in normoxia but displayed Fig. 3 (continued) increased sensitivities under hypoxia, hypoxia reduced Mcl-1 expression to barely detectable levels (Fig. 4b) .
In MOLM-13 cells, GDC-0941 or ABT-737 alone did not reduce Mcl-1 levels but the GDC-0941/ABT-737 combination markedly downregulated Mcl-1 levels in normoxic and hypoxic conditions (Fig. 4a) . Mcl-1 is a substrate for caspasemediated degradation, and the GDC-0941/ABT-737 combination increased cleavage of pro-caspase-3, suggesting an activation of the mitochondrial apoptotic pathway by combined use of these two agents. Expression levels of antiapoptotic Bcl-2 and Bcl-X L and proapoptotic Bim remained unchanged. We next investigated whether GDC-0941 facilitates BAX activation by ABT-737 in MOLM-13 and OCI-AML3 cells. GDC-0941 increased ABT-737-induced loss of the mitochondrial membrane potential (Δψ m ) and BAX conformational change in MOLM-13 cells (Fig. 5a, Supplementary Fig. 3 ). These findings suggest that inhibition of PI3K/Akt signaling stimulates ABT-737-induced mitochondrial apoptosis, resulting in caspase activation and caspase-dependent Mcl-1 cleavage. Similar albeit less pronounced effects were seen in OCI-AML3 cells co-treated with GDC-0941/ABT-737 (Fig. 5b) . (Fig. 6b) . However, the overall effect was more evident in cells with low Mcl-1 levels. Consistent with our published data [10] , downregulation of Mcl-1 increased cell sensitivity to ABT-737 through induction of apoptosis but did not induce cell-cycle arrest (Fig. 6c-e, Supplementary Fig. 4A,B) . Similar to the findings in parental OCI-AML3 cells, hypoxia sensitized scrambled shRNA-infected OCI-AML3 to ABT-737-induced growth inhibition and apoptosis induction ( Fig. 6c, d; Supplementary Fig. 4A ). In turn, hypoxia, which by itself decreased Mcl-1 levels to the extent of knockdown in transfected cells (Fig. 6f) , did not enhance ABT-induced apoptosis in Mcl-1 knockdown OCI-AML3 cells (Fig. 6d) , indicating that Mcl-1 downregulation is the main mechanism of increased sensitivity of leukemic cells to ABT-737 under low oxygen conditions. The GDC-0941/ABT-737 combination further increased in apoptosis under normoxic and hypoxic conditions in both scrambled shRNA-and Mcl-1 shRNAtransfected OCI-AML3 cells; however, cell death was significantly higher in cells with low Mcl-1 levels.
Discussion
Our results suggest that the class I PI3K inhibitor GDC-0941 enhances ABT-737-mediated mitochondrial apoptosis in AML cells. Many small-molecule inhibitors have been developed to target the PI3K/Akt/mTOR pathway, an attractive candidate for targeted therapeutics; some are in clinical trials, and some have been approved for cancer therapy [3] . GDC-0941, which as a single agent predominantly induces G 1 cellcycle arrest with minimal apoptosis, promoted ABT-737-induced apoptosis with BAX activation, suggesting that blockade of PI3K/Akt signaling enhances mitochondrial outer membrane permeabilization by ABT-737 in AML cells. The efficacy of BH3 mimetic ABT-737 as a single agent is known to be limited because it binds tightly to Bcl-2, Bcl-xL , and Bclw but not to Mcl-1 [10] . Previous reports suggest that high expression of Mcl-1 contributes to resistance to ABT-737 and that decreased expression of Mcl-1 confers sensitivity to ABT-737 [10, 11, 30] . Mcl-1 blocks cytochrome c release from mitochondria in part by heterodimerizing with proapoptotic member of the Bcl-2 family BAX, thereby preventing BAX/ BAK activation and mitochondrial outer membrane permeabilization and finally maintaining mitochondrial homeostasis. Therefore, a strategy that targets Mcl-1 is critical to sensitize tumor cells to ABT-737, including AML [10, 11] . The shRNA or scrambled shRNA as described in the "Materials and methods". a Cells were cultured in the presence of escalating doses of GDC-0941 and ABT-737 using fixed ratios. After 48 h, the effects on cell growth were evaluated by viable cell counts using the trypan blue exclusion method. Graphs show the mean±SEM of results of three independent experiments. b Combination index (CI) plots were generated using CalcuSyn software. c The viable cells' number was measured by trypan blue exclusion assay. Annexin V-positive fractions (d) and DNA content (e) were measured by flow cytometry. Graphs show the means±-SEM of results of three independent experiments. *p<0.05, **p<0.01. f Expression of various proteins in OCI-AML cells transfected Mcl-1 shRNA or scrambled control shRNA that had been treated for 24 h with 0.5 μM GDC-0941 and/or 0.25 μM ABT-737 under normoxic or hypoxic conditions. α-tubulin was used to confirm equal loading of proteins. Results are representative of three independent experiments. Intensity of the immunoblot signals after background subtraction was quantified using ImageJ software, and the relative intensity compared to that of α-tubulin was calculated Very recently, Spender and Inman reported that the combined inhibition of PI3K/Akt/mTOR and ABT-737 induced synergistic caspase activation and increase in Bim/Mcl-1 expression ratios, which was associated with a loss of c-Myc expression in Burkitt's lymphoma cells [7] . The synergistic apoptosis induction by combination of c-Myc inhibitor with ABT-737 suggests that c-Myc, the downstream target of PI3K/Akt/mTOR, promotes resistance to ABT-737 [7] . cMyc is one of the direct target gene products of Stat-5 which cross-talks with Akt/mTOR and directly targets Bcl-2 and Bcl-xL [6] , and the combined targeting of Akt/mTOR using rapamycin and of Bcl-2 and Bcl-xL using ABT-737 has been shown to suppress the survival of Stat-5-dependent myeloproliferative neoplasms [35] . Given the proposed importance of c-Myc in AML biology [36] , further studies dissecting the role of c-Myc in ABT-737 resistance may be informative.
In this study, we further investigated efficacy of this combination in AML cells co-cultured with MSCs in hypoxic conditions, mimicking pathologic conditions of the leukemic BM microenvironment. It has been recently reported that matrix-attached tumor cells initiate an adaptive response involving upregulation of Bcl-2 antiapoptotic family proteins Bcl-2 and Bcl-xL through cap-independent translation and FOXO-mediated transcription [37] . In turn, combined inhibition of Bcl-2 and PI3K/mTOR was capable of effectively abrogating matrix-associated resistance of cancer cells [37] . Co-culture with MSC promoted phosphorylation of AKT and of mTOR downstream target pS6K in AML cells, consistent with our previous findings [19] . Although both Bcl-2 and Mcl-1 have been reportedly induced in leukemic cells in coculture with stromal cells [38] , we did not observe change in the expression levels of these proteins. These discrepancies are likely related to the type of the stromal cells used (stromal cell lines vs. human BM-derived stromal cells in our study). Nevertheless, our published data are consistent with findings in other studies and confirm observation that human BMderived MSC confer protection against traditionally used chemotherapeutic agents [39] . It is conceivable that stromainduced activation of PI3K/AKT/mTOR pathway mediates resistance through posttranslational modulation of Bcl-2 family proteins or transcriptional modification of other apoptotic players through FOXO transcriptional factor. Of note, we observed better protective effects of AML patient BMderived MSCs against GDC-0941/ABT-737 compared to normal BM MSCs, and this finding warrants further systematic studies utilizing leukemia-derived stromal cells. Overall, our data demonstrate the potential of PI3K and Bcl-2/Bcl-xL inhibitors to cause impressive inhibition of AML cell growth even under protective conditions of stromal co-cultures.
We have further explored the effect of hypoxia on GDC-0941/ABT-737 efficacy. Recent studies demonstrated that hypoxia downregulated Mcl-1 through HIF-1α-dependent orindependent mechanisms, in a cell type-dependent fashion [18] . These findings indicate that hypoxia, a known resistance factor, may paradoxically mediate enhanced sensitivity of hypoxic tumor cells to BH3 mimetic ABT-737. Consistent with the published data, we found that hypoxia, a condition prevalent in leukemic BM, reduced expression levels of antiapoptotic Mcl-1 in MOLM-13 and OCI-AML3 cells and reversed the resistance to ABT-737 in Mcl-1-dependent OCI-AML3 cells. While knockdown of Mcl-1 sharply increased sensitivity of OCI-AML3 cells to ABT-737 under normoxic conditions, no further sensitization was conferred by culturing cell in hypoxic environment, indicating that reduction of Mcl-1 is a main mediator of increased sensitivity of AML cells under hypoxia. Although we did not observe enhanced sensitivity to ABT-737 or ABT-737/GDC-0941 in HL-60 and MOLM-13 under hypoxic conditions, pharmacological interactions between two targeted agents remained synergistic. This synergism was maintained in shMcl-1-infected OCI-AML3, pointing out to the additional mechanisms of sensitization to cell death upon combined blockade of both pathways. Taken together, our results showed that albeit hypoxia reversed Mcl-1-dependent resistance to ABT-737, in normoxia GDC-0941/ABT-737 combination was synergistic regardless of Mcl-1 silencing. These findings suggest the contribution of other potential mechanisms regulating mitochondrial apoptosis upon GDC-0941/ABT-737 treatment. Rahmani et al. [34] have recently demonstrated that PI3K/Akt inhibition increased Bim binding to Bcl-2/Bcl-xL which was abrogated by ABT-737, while combined treatment of PI3K/Akt inhibitor with ABT-737 diminished Bax/Bak binding to Mcl-1, Bcl-2, and Bcl-xL. These findings suggest that apoptosis induction induced by GDC-0941/ABT-737 combination is a multifactorial process, involving release of Bim from Bcl-2/Bcl-xL or Bak/Bax from Mcl-1/Bcl-2/Bcl-xL complexes in addition to Mcl-1 downregulation, which ultimately results in apoptosis induction through Bax/Bak activation.
Overall, these findings indicate that (1) high expression of Mcl-1 does not necessarily translate to the resistance to ABT-737 in AML blasts residing within hypoxic conditions of BM microenvironment and (2) dual inhibition of Bcl-2 and PI3K pathways inhibits AML cell survival in a synergistic manner and may be particularly applicable under the pathologic conditions of leukemic BM microenvironment shown by us to promote resistance to cytotoxic chemotherapeutic agents.
In summary, the concomitant inhibition of PI3K and antiapoptotic Bcl-2 family proteins warrants further exploration as attractive therapeutic modality in AML, capable of overcoming specific mechanisms of matrix-associated and hypoxiainduced AML cell survival in the BM microenvironment.
